scholarly journals Treatment of gastric carcinoids type 1 with the gastrin receptor antagonist netazepide (YF476) results in regression of tumours and normalisation of serum chromogranin A

2012 ◽  
Vol 36 (11-12) ◽  
pp. 1067-1075 ◽  
Author(s):  
R. Fossmark ◽  
Ø. Sørdal ◽  
C. S. Jianu ◽  
G. Qvigstad ◽  
I. S. Nordrum ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Chromogranin A ◽  
Gastrin Receptor ◽  
Gastric Carcinoids

57 Treatment of Gastric Carcinoids Type 1 With the Gastrin Receptor Antagonist YF476 Results in Regression of Tumours and Normalisation of Serum Chromogranin A

2012 ◽  
Vol 142 (5) ◽  
pp. S-15 ◽  
Author(s):  
Reidar Fossmark ◽  
Øystein Sørdal ◽  
Constantin S. Jianu ◽  
Gunnar Qvigstad ◽  
Malcolm J. Boyce ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Chromogranin A ◽  
Gastrin Receptor ◽  
Gastric Carcinoids

The gastrin receptor antagonist netazepide (YF476) in patients with type 1 gastric enterochromaffin-like cell neuroendocrine tumours

2016 ◽  
Vol 28 (11) ◽  
pp. 1345-1352 ◽  
Author(s):  
Liv Sagatun ◽  
Patricia Mjønes ◽  
Constantin S. Jianu ◽  
Malcolm Boyce ◽  
Hege L. Waldum ◽  
...  
Keyword(s):  
Receptor Antagonist ◽  
Neuroendocrine Tumours ◽  
Gastrin Receptor

scholarly journals Plasma chromogranin A in patients with autoimmune chronic atrophic gastritis, enterochromaffin-like cell lesions and gastric carcinoids

2005 ◽  
Vol 152 (3) ◽  
pp. 443-448 ◽  
Author(s):  
M Peracchi ◽  
C Gebbia ◽  
G Basilisco ◽  
M Quatrini ◽  
C Tarantino ◽  
...  
Keyword(s):  
Cell Proliferation ◽  
Healthy Subjects ◽  
Chromogranin A ◽  
Neuroendocrine Tumours ◽  
Chronic Atrophic Gastritis ◽  
Cell Hyperplasia ◽  
Gastric Carcinoids ◽  
Ecl Cell ◽  
Design And Methods

Objective: In atrophic body gastritis (ABG) chronic hypergastrinaemia stimulates enterochromaffin-like (ECL) cell proliferation with development of cell hyperplasia, dysplasia and possibly type-1 gastric carcinoids. As circulating chromogranin A (CgA) levels are a marker of neuroendocrine tumours, we evaluated the clinical usefulness of CgA assay in ABG patients to detect those with carcinoids. Design and methods: Plasma CgA levels were measured using a commercial ELISA in 45 healthy volunteers, nine patients with type-1 gastric carcinoids and 43 consecutive ABG patients (21 without and 22 with ECL cell hyperplasia/dysplasia). Results: CgA levels were significantly higher in ABG patients with and without gastric carcinoids than in healthy subjects (P < 0.001). The highest values occurred in patients with carcinoids (median (interquartile range): 58.1 (44.5–65.3) U/l) and with ECL cell hyperplasia/dysplasia (35.5 (31.8–48.65) U/l) but there were no significant differences in CgA among the various subgroups of ABG patients classified according to ECL cell status. Nevertheless, in ABG patients without carcinoids CgA values correlated with the presence and severity of ECL cell lesions (r s = 0.428, P < 0.01). The sensitivity and specificity of the CgA assay in identifying patients with carcinoids were 100 and 23% respectively. Conclusions: CgA plasma levels reflect the histological degree of ECL cell lesions in patients with ABG but the assay specificity is too low to detect among these patients those with gastric carcinoids.

scholarly journals Clinical symptoms, hormone profiles, treatment, and prognosis in patients with gastric carcinoids

Gut ◽  
1998 ◽  
Vol 43 (2) ◽  
pp. 223-228 ◽  
Author(s):  
D Granberg ◽  
E Wilander ◽  
M Stridsberg ◽  
G Granerus ◽  
B Skogseid ◽  
...  
Keyword(s):  
Liver Metastasis ◽  
Chromogranin A ◽  
Clinical Symptoms ◽  
Chronic Atrophic Gastritis ◽  
Gastric Carcinoid ◽  
Interferon Α ◽  
Gastric Carcinoids ◽  
Type 3

Background—Type 1 gastric carcinoids are associated with hypergastrinaemia and chronic atrophic gastritis, type 2 occur in patients with multiple endocrine neoplasia type 1 combined with Zollinger-Ellison syndrome, and type 3 lack any relation to hypergastrinaemia. Type 1 tumours are usually benign whereas type 3 are highly malignant.Aims—To identify possible tumour markers in patients with gastric carcinoids.Patients/method—Nine patients with type 1, one with type 2, and five with type 3 were evaluated with regard to symptoms, hormone profile, and prognosis.Results—Plasma chromogranin A was increased in all patients but was higher (p<0.01) in those with type 3 than those with type 1 carcinoids. All patients with type 3 carcinoids died from metastatic disease, but none of the type 1 patients died as a result of their tumours. One type 1 patient with a solitary liver metastasis received interferon α and octreotide treatment. Nine months later, the metastasis was no longer detectable. She is still alive eight years after diagnosis, without recurrent disease. This represents the only reported case of foregut carcinoid with an unresectable liver metastasis that seems to be have been cured by biotherapy.Conclusions—Plasma chromogranin A appears to be a valuable tumour marker for all types of gastric carcinoid. Combination therapy with interferon α and octreotide may be beneficial in patients with metastasising type 1 gastric carcinoids.

Development of silent gastric carcinoid in a type 1 diabetic patient with primer hypothyreosis

2007 ◽  
Vol 148 (35) ◽  
pp. 1667-1671 ◽  
Author(s):  
Anikó Somogyi ◽  
Éva Ruzicska ◽  
Timea Varga ◽  
Károly Rácz ◽  
Géza Nagy
Keyword(s):  
Diabetic Patient ◽  
Chromogranin A ◽  
Gastric Carcinoid

Az 1-es típusú cukorbetegség gyakran társul egyéb autoimmun kórképekkel. A parietalis sejtellenes antitestek (PCA), melyek az 1-es típusú cukorbetegek mintegy 20%-ában megtalálhatók, autoimmun gastritis és anaemia perniciosa jelenlétére figyelmeztetnek. A PCA-k a gyomor-H + /K + ATP-ázt károsítják, és hypo-/achlorhydriát, hypergastrinaemiát okozhatnak. Ennek következtében az enterochromaffin-szerű (ECL) sejtek hyper-/dysplasiaja alakulhat ki, mely carcinoid gyomortumor kialakulására hajlamosít. Az ECL-sejtek hyperplasiájából fejlődő gyomorcarcinoidok az autoimmun gastritises vagy anaemia perniciosában szenvedő betegek 4–9%-ában alakulnak ki. A 29 éves, 6 éve 1-es típusú diabéteszben szenvedő, 8 éves kora óta primer hypothyreosis miatt pajzsmirigyhormon-szubsztitúcióban részesülő nőbetegünknél gyomorpanaszok miatt felső panendoszkópia és biopsziás vizsgálat történt. Az endoszkópia többszörös kicsi polipokat mutatott a fundus területén nonantral hypergastrinaemiás (A-típusú) atrophiás gastritissel. A parietalis sejtantitest-vizsgálat pozitív volt, a szérum-chromogranin-A koncentrációja (CgA) 289,7 ng/ml (norm: 98 ng/ml alatt), a TSH-szint 9,93 mIU/L volt. A szövettani vizsgálat carcinoid tumort igazolt. Octreotidterápiát követően parciális gastrectomiát végeztek. Műtét után a szérum-chromogranin-A-szint normalizálódott. A nonatral, többszörös polipok néma neuroendocrin tumort takarhatnak, melyek rendszerint lassan növekvő, benignus viselkedésű endokrin daganatok, de magas malignitású endokrin karcinómák is lehetnek. A specifikus szérum- vagy szöveti chromogranin-A (CgA) és egyéb endokrin tumorra utaló markerek mérésének elérhetővé válásával e tumorok könnyen felismerhetők lehetnek a klinikus számára.

Sign in / Sign up

Export Citation Format

Share Document